QbD-driven development of dissolving microneedle patch loaded with ultradeformable liposomes encapsulated Noopept: Exploring a patient friendly, once-daily option to manage dementia.

Srivastava PK, Thakkar HP

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences11 Jun 2021Cited by 9 (Europe PMC)

PMID34126240DOI10.1016/j.ejps.2021.105909PepBankPUB-34126240

Publisher page PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Noopept (omberacetam) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Noopept (omberacetam).

01AnimalNot a test of Noopept (omberacetam) aloneAnimal study (in vivo)Pharmacokinetics
In Sprague Dawley rats, the noopept patch increased relative bioavailability 3-fold compared with oral noopept suspension.
In plain wordsIn rats, the noopept patch increased relative bioavailability 3-fold compared with oral noopept suspension.
Peptide
Noopept (omberacetam)
Outcome
IncreaseRelative bioavailability
Study
ratn: not reported in source
Sprague Dawley rats
Comparator
Oral NPT suspension
Outcome group
Pharmacokinetics · Pharmacology
Measurements
Relative bioavailability increase
3 fold
Compared with oral NPT suspension
Source sentences
Summary
A 3-fold increase in relative bioavailability with similar pharmacological response as compared to oral NPT suspension was also observed during PK-PD studies in Sprague Dawley rats.
In this study, Noopept (omberacetam) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Noopept (omberacetam).
Report a problemFND-3412624007
02AnimalNot a test of Noopept (omberacetam) aloneAnimal study (in vivo)Efficacy outcome
In Sprague Dawley rats, the noopept patch produced a pharmacological response similar to oral noopept suspension.
In plain wordsIn rats, the noopept patch produced a similar pharmacological response to oral noopept suspension.
Peptide
Noopept (omberacetam)
Outcome
No significant changePharmacological response
Study
ratn: not reported in source
Sprague Dawley rats
Comparator
Oral NPT suspension
Outcome group
Overall treatment effect · Nervous system and cognition
Source sentences
Summary
A 3-fold increase in relative bioavailability with similar pharmacological response as compared to oral NPT suspension was also observed during PK-PD studies in Sprague Dawley rats.
In this study, Noopept (omberacetam) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Noopept (omberacetam).
Report a problemFND-3412624008
03LabNot a test of Noopept (omberacetam) aloneEx vivo tissuePharmacokinetics
Across pig ear skin, the noopept liposome microneedle patch increased steady state flux 6.5-fold compared with noopept suspension.
In plain wordsIn lab tests of pig skin, the noopept patch increased steady state flux 6.5-fold compared with noopept suspension.
Peptide
Noopept (omberacetam)
Outcome
IncreaseSteady state skin flux
Study
pign: not reported in source
Full thickness pig ear skin
Comparator
NPT suspension
Outcome group
Pharmacokinetics · Pharmacology
Measurements
Steady state flux increase
6.5 fold
Compared with NPT suspension
Source sentences
Summary
NPT UDL MNP showed a 6.5-fold increase in steady state flux across full thickness pig ear skin as compared to NPT suspension.
In this study, Noopept (omberacetam) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Noopept (omberacetam).
Report a problemFND-3412624006
04LabNot a test of Noopept (omberacetam) aloneIn vitro (cells)Safety outcome
In HaCaT cells, viability after exposure to the noopept liposome microneedle matrix was 89.74%.
In plain wordsIn cells, viability after exposure to the noopept patch matrix was 89.74%.
Peptide
Noopept (omberacetam)
Outcome
Not applicableCell viability
Study
humann: not reported in source
HaCaT cells exposed to NPT UDL MNP matrix
Outcome group
Adverse events · Skin and wound
Measurements
Cell viability
89.74%
After NPT UDL MNP matrix exposure
Source sentences
Summary
In vitro viability of HaCaT cells after exposure to NPT UDL MNP matrix was found to be 89.74% supporting the formulation as safe for transdermal application.
In this study, Noopept (omberacetam) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Noopept (omberacetam).
Report a problemFND-3412624005
05LabNot a test of Noopept (omberacetam) aloneIn vitro (cell-free)Activity measurement
In formulation tests, the noopept liposome microneedle patch had sufficient axial needle fracture force to breach the stratum corneum.
In plain wordsIn lab tests, the noopept patch had enough needle strength to breach the outer skin layer.
Peptide
Noopept (omberacetam)
Outcome
Not applicableAxial needle fracture force
Study
n: not reported in source
Noopept liposome microneedle patch
Outcome group
Formulation, delivery and stability · Pharmacology
Measurements
Axial needle fracture force
0.688 N
NPT UDL MNP
Source sentences
Summary
NPT UDL MNP possessed axial needle fracture force of 0.688 N which was sufficient enough to breach stratum corneum.
In this study, Noopept (omberacetam) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Noopept (omberacetam).
Report a problemFND-3412624001
06LabNot a test of Noopept (omberacetam) aloneIn vitro (cell-free)Activity measurement
In physical stability tests, redispersed noopept liposomes retained an identical vesicle shape compared with optimized liposomes.
In plain wordsIn lab tests, redispersed noopept liposomes had the same shape as optimized liposomes.
Peptide
Noopept (omberacetam)
Outcome
No significant changeVesicle shape stability
Study
n: not reported in source
Redispersed noopept liposomes from microneedle matrix
Comparator
Optimized NPT UDL
Outcome group
Formulation, delivery and stability · Pharmacology
Source sentences
Summary
Physical stability evaluation revealed that NPT UDL re-dispersion obtained from MNP matrix dissolution possessed identical vesicle shape and size while retaining > 99% NPT when compared to optimized NPT UDL.
In this study, Noopept (omberacetam) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Noopept (omberacetam).
Report a problemFND-3412624002
07LabNot a test of Noopept (omberacetam) aloneIn vitro (cell-free)Activity measurement
In physical stability tests, redispersed noopept liposomes retained an identical vesicle size compared with optimized liposomes.
In plain wordsIn lab tests, redispersed noopept liposomes had the same size as optimized liposomes.
Peptide
Noopept (omberacetam)
Outcome
No significant changeVesicle size stability
Study
n: not reported in source
Redispersed noopept liposomes from microneedle matrix
Comparator
Optimized NPT UDL
Outcome group
Formulation, delivery and stability · Pharmacology
Source sentences
Summary
Physical stability evaluation revealed that NPT UDL re-dispersion obtained from MNP matrix dissolution possessed identical vesicle shape and size while retaining > 99% NPT when compared to optimized NPT UDL.
In this study, Noopept (omberacetam) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Noopept (omberacetam).
Report a problemFND-3412624003
08LabNot a test of Noopept (omberacetam) aloneIn vitro (cell-free)Activity measurement
In physical stability tests, redispersed liposomes retained more than 99% of noopept compared with optimized liposomes.
In plain wordsIn lab tests, redispersed liposomes retained more than 99% of noopept compared with optimized liposomes.
Peptide
Noopept (omberacetam)
Outcome
Not applicableNoopept retention
Study
n: not reported in source
Redispersed noopept liposomes from microneedle matrix
Outcome group
Formulation, delivery and stability · Pharmacology
Measurements
NPT retention
> 99%
Redispersion compared with optimized NPT UDL
Source sentences
Summary
Physical stability evaluation revealed that NPT UDL re-dispersion obtained from MNP matrix dissolution possessed identical vesicle shape and size while retaining > 99% NPT when compared to optimized NPT UDL.
In this study, Noopept (omberacetam) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Noopept (omberacetam).
Report a problemFND-3412624004

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.